tumours (***P < 0.0001). Some spread in the vessel density was apparent, particularly within the MC38 cohort, and so the relationship with tumour volume was assessed (B, C). However, no significant correlations were found between tumour vessel density and increasing tumour volume, again indicating that tumour vascularity per unit tumour area remained largely constant across the range of tumour sizes studied (in accord with the T 2 * analysis in Figure   S2 , F).
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Supplementary Methods
Synthesis of dextran coated nanoparticles
A 1 litre 3 neck round flask was charged with 6.75 g of FeCl 3 ·6H 2 O (Sigma Aldrich, UK), 75 g of dextran 10 Pharmacological grade (Pharmacosmos, batch Nr. HR210) and 100 ml of water. The sample was stirred using an overhead stirrer at 300 rpm for 15 min until complete dissolution of the solids, and deoxygenated thoroughly by repeated cycles of vacuum assisted by sonication and argon flushing. After the first deoxygenation cycle, 3.0 g of FeCl 2 ·4H 2 O (Sigma Aldrich, UK) in 25 ml of water was added and the solution was deoxygenated by the above procedure (4 times). While being stirred at 600 rpm, 20 ml of 30 % NH 4 OH (Sigma Aldrich, UK) was added at a rate of 168 ml/h. The reaction was heated to 80 ºC and then stirred at this temperature for 1 hour. The solution was cooled and dialyzed against water in a Spectra/Por 2 membrane (MWCO 6-8000) for 21 hours against 5 litter of water with water changes after 2 and 4 h.
Particle size was measured by dynamic light scattering in a Zetasizer Nano ZS (Malvern, UK). Briefly, 20 μl of particles were dispersed in 700 μl of water, the sample was shaken for 15 min and placed in polystyrene cuvette. Size measurement was performed in triplicate at 25
°C and results were analysed using the general purpose analysis model provided by the instrument software. The product particle size was 20.5 ± 8.9 nm with a PdI of 0.188.
